CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

Mené sur 102 patientes atteintes d'un cancer du sein triple négatif de stade métastatique, cet essai de phase II évalue l'efficacité, du point de vue de la survie globale, et la toxicité, notamment du point de vue de la durée d'une neutropénie sévère, de l'ajout du trilaciclib (un inhibiteur de CDK4/6) à une chimiothérapie combinant gemcitabine et carboplatine

Résumé en anglais

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were developed on the premise that they would inhibit the proliferation of cancer cells by arresting them in the G1 phase of the cell cycle. Consistent with this idea, CDK4/6 inhibitors have proven to be highly efficacious in the treatment of metastatic hormone receptor-positive breast cancers, most of which depend on the cyclin D-CDK4/6–retinoblastoma protein axis for sustained cancer cell proliferation. By contrast, the use of CDK4/6 inhibitors in triple-negative breast cancers, a group of tumours that frequently shows genomic or functional loss of retinoblastoma protein has received considerably less enthusiasm.